Ignite Creation Date:
2025-12-24 @ 1:33 PM
Ignite Modification Date:
2026-01-01 @ 12:30 AM
Study NCT ID:
NCT01162395
Status:
COMPLETED
Last Update Posted:
2016-01-12
First Post:
2010-07-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Open Label Prostate Cancer Study
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D011471', 'term': 'Prostatic Neoplasms'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D009362', 'term': 'Neoplasm Metastasis'}], 'ancestors': [{'id': 'D005834', 'term': 'Genital Neoplasms, Male'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D005832', 'term': 'Genital Diseases, Male'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D011469', 'term': 'Prostatic Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D009385', 'term': 'Neoplastic Processes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C583656', 'term': 'AZD3514'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 64}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2010-08'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2016-01', 'completionDateStruct': {'date': '2015-10', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2016-01-11', 'studyFirstSubmitDate': '2010-07-13', 'studyFirstSubmitQcDate': '2010-07-13', 'lastUpdatePostDateStruct': {'date': '2016-01-12', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2010-07-14', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2013-03', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'To investigate the safety and tolerability of AZD3514 when given orally to patients with CRPC.', 'timeFrame': 'At every visit.'}], 'secondaryOutcomes': [{'measure': 'To define the MTD, if possible, a lower biologically-effective dose(s) or maximum feasible dose (if decided by the Safety Review Committee (SRC) and AstraZeneca).', 'timeFrame': 'After each Cohort.'}, {'measure': 'To characterise the PK of AZD3514 after a single oral dose and at steady state after multiple oral doses.', 'timeFrame': 'After each Cohort.'}, {'measure': 'To obtain an assessment of the activity of AZD3514 as monotherapy and/or in combination with abiraterone acetate on the circulating levels of prostate-specific antigen (PSA).', 'timeFrame': 'Visits 1, 4, 6, 7, 9, 10, follow-up visits, discontinuation visit'}, {'measure': 'To obtain a preliminary assessment of the anti-tumour activity of AZD3514 as monotherapy and/or in combination with abiraterone acetate by evaluation of counts of Circulating Tumour Cells (CTCs).', 'timeFrame': 'Visits 1, 6, 8, 9, 10, follow-up visits, discontinuation visit'}, {'measure': 'To obtain an assessment of the activity of AZD3514 as monotherapy and/or in combination with abiraterone acetate on the circulating levels of prostate-specific antigen (PSA).', 'timeFrame': 'Visits 1, 10, follow-up visits, discontinuation visit'}, {'measure': 'To investigate safety, tolerability, MTD (and/or biologically-effective dose(s) or maximum feasible dose) and PK of AZD3514 and abiraterone when administered in combination, in patients who have not received prior treatment with abiraterone acetate', 'timeFrame': 'At every visit'}, {'measure': 'To compare the PK of AZD3514 monotherapy in patients who have been fed or fasted before the administration of study treatment', 'timeFrame': 'At visits 2 and 4'}, {'measure': 'To investigate the effect of AZD3514 on biomarkers of AR expression in paired pre- and post-dose tumour biopsies.', 'timeFrame': 'July 2012 - Feb 2013'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Prostate Cancer', 'Tumour', 'Castration Resistant', 'Prostate Androgen Receptor Down Regulator', 'Metastatic'], 'conditions': ['Prostate Cancer']}, 'referencesModule': {'references': [{'pmid': '27581751', 'type': 'DERIVED', 'citation': 'James GD, Symeonides SN, Marshall J, Young J, Clack G. Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data. BMC Cancer. 2016 Aug 31;16(1):703. doi: 10.1186/s12885-016-2702-6.'}], 'seeAlsoLinks': [{'url': 'http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1380&filename=D3760C00001_Clinical_Trial_Disclosure_Synopsis.pdf', 'label': 'D3760C00001 Clinical Report Synopsis'}]}, 'descriptionModule': {'briefSummary': 'The main purpose of the study is to investigate the safety and tolerability of AZD3514 when given orally to patients with castration-resistant prostate cancer (CRPC)'}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '130 Years', 'minimumAge': '20 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Males aged 20 years or older.\n* Histologically or Cytologically proven diagnosis of prostate cancer for which no standard therapy is currently considered appropriate.\n* Documented evidence of metastatic prostate cancer\n* Presence of progressive disease defined as one or more:\n* Biochemical progression of the prostate cancer\n* Progression as defined by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 guidelines\n* Two or more new metastatic bone lesions from bone scans from a previous assessment\n* Serum testosterone concentration less or equals 50 ng/dL\n* World Health Organization (WHO) performance status 0 to 1 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks.\n* Sexually active males should be willing to use condoms\n* For inclusion in the AZD3514 administered in combination with abiraterone acetate cohort(s), patients must:\n* Have received prior chemotherapy containing or based on docetaxel\n* Not have received prior treatment with abiraterone acetate, MDV3100, TAK700, TOK001 or other similar therapies which target the AR axis or with selective AR down-regulator-like properties\n* For inclusion in the AZD3514 administered in combination with abiraterone acetate in patients who are currently receiving abiraterone acetate cohort(s), patients must:\n\n 1. Have been stable on abiraterone acetate abiraterone acetate for ≥ 4 months (i.e. stable PSA values) and have achieved ≥ 50% reduction in PSA while being treated with abiraterone acetate\n 2. Have evidence of biochemical progression (PSA) of the prostate cancer, as defined in inclusion number 5 (except for the withdrawal of abiraterone acetate as an anti-androgen therapy)\n* For inclusion in the paired (same lesion) tumour biopsy research, patients must:\n\n 1. Provide informed consent for paired tumour biopsy sampling\n 2. Have bone or soft tissue lesions that are suitable for paired biopsy sampling\n\nExclusion Criteria:\n\n* Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAEv4) grade 1 except for alopecia or toxicities related to the use of gonadotropin-releasing hormone agonists\n* Medically important spinal cord compression or brain metastases\n* Medically important evidence of severe or uncontrolled systemic disease\n* History of hypersensitivity to active or inactive excipients of AZD3514 or drugs with a similar chemical structure or class to AZD3514\n* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD3514\n* Inadequate bone marrow reserve or organ function\n* Any medically important factors identified from electrocardiogram (ECG) measurements\n* Concurrent or recent treatment with certain medications or medical procedures\n\nThe following criteria exclude patients from entering the AZD3514 administered in combination with abiraterone acetate cohort(s):\n\n* As judged by the investigator, any evidence of severe or uncontrolled systemic diseases or conditions, including adrenocortical insufficiency or a history of cardiovascular disease including heart failure (currently there are no randomized data for the use of abiraterone acetate in patients with LVEF \\< 50% or NYHA Class III or IV heart failure), which would make it undesirable for the patient to participate in the trial. See the full local prescribing information for abiraterone acetate for more detail\n* Child-Pugh class B and C hepatic impairment\n* If unable to fast for ≥ 2 hours prior to taking a dose to ≥ 1 hour post dose\n* Received abiraterone acetate treatment previously\n* Known hypersensitivity to components of prednisone or prednisolone\n* Any systemic fungal infections'}, 'identificationModule': {'nctId': 'NCT01162395', 'briefTitle': 'Open Label Prostate Cancer Study', 'organization': {'class': 'INDUSTRY', 'fullName': 'AstraZeneca'}, 'officialTitle': 'A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD3514 in Patients With Metastatic Castration-Resistant Prostate Cancer.', 'orgStudyIdInfo': {'id': 'D3760C00001'}, 'secondaryIdInfos': [{'id': '2010-020232-19', 'type': 'EUDRACT_NUMBER'}, {'id': 'IND 111707'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'A', 'description': 'Ascending doses of AZD3514 administered orally to patients to define the maximum tolerated dose (MTD)', 'interventionNames': ['Drug: AZD3514']}], 'interventions': [{'name': 'AZD3514', 'type': 'DRUG', 'description': 'Patients will be given AZD3514 orally as a single dose, and then multiple once daily dosing following a 5-9 day washout.', 'armGroupLabels': ['A']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'city': 'Amsterdam', 'country': 'Netherlands', 'facility': 'Research Site', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'city': 'Glasgow', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 55.86515, 'lon': -4.25763}}, {'city': 'Manchester', 'country': 'United Kingdom', 'facility': 'Research Site', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}, {'city': 'Surrey', 'country': 'United Kingdom', 'facility': 'Research Site'}], 'overallOfficials': [{'name': 'Tony Elliott, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'The Christie Hospital'}, {'name': 'Glen Clack, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'AstraZeneca'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'AstraZeneca', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}